Factor VIII Dose Calculator
Factor VIII Dose Calculator
Dose factor VIII replacement in haemophilia A from weight and the rise you need, with the target peak levels the WFH sets for each type of bleed — and the response that should make you think of an inhibitor.
Factor VIII Dose
Weight × rise × 0.570 kg, baseline 1 IU/dL, target peak 60 IU/dL for a joint bleed
Formula
Desired rise = target peak − baseline level
Because 1 IU/kg of standard half-life factor VIII raises plasma FVIII by about 2 IU/dL
- × 0.5
- the reciprocal of the recovery. WFH states that each IU of plasma-derived or standard half-life recombinant factor VIII per kg raises the plasma level by approximately 2 IU/dL, so half an IU per kg is needed for each 1 IU/dL of rise
- desired rise, not desired peak
- subtract the baseline. In severe haemophilia A the baseline is under 1 IU/dL and the two are nearly identical; in mild disease with a baseline of 20 IU/dL, using the peak instead of the rise overdoses by a third
- IU/dL and % of normal
- the same number. A factor VIII of 60 IU/dL is 60% of normal activity, which is why the formula appears written both ways and why the two are interchangeable in it
- what this does not cover
- extended half-life products, whose dosing intervals differ; emicizumab, which is not measured or dosed this way at all; and patients with inhibitors, who need bypassing agents rather than more factor VIII
Worked example
70 kg, baseline 1 IU/dL, target peak 60 IU/dL for a joint bleed
Desired rise = 60 − 1 = 59 IU/dL
70 × 59 × 0.5 = 2,065 IU
That is about 29.5 IU/kg, consistent with 1 IU/kg raising factor VIII by roughly 2 IU/dL
Round up to whole vials on the assayed potency printed on each vial; do not split a vial to reach 2,065 exactly
Half-life is about 12 hours in adults, so plan a repeat at 12 to 24 hours rather than treating this as a single dose
WFH peak factor VIII levels and duration by type of bleed
| Bleed or procedure | Higher-dose peak (IU/dL) | Lower-dose peak (IU/dL) | Duration |
|---|---|---|---|
| Joint (haemarthrosis) | 40–60 | 10–20 | 1–2 days |
| Superficial muscle | 40–60 | 10–20 | 2–3 days |
| Iliopsoas or deep muscle — initial | 80–100 | 20–40 | 1–2 days, then maintenance 3–5 days |
| Intracranial — initial | 80–100 | 50–80 | 1–7 days, then maintenance 8–21 days |
| Throat or neck — initial | 80–100 | 30–50 | 1–7 days, then maintenance |
| Gastrointestinal — initial | 80–100 | 30–50 | 7–14 days, then maintenance |
| Renal | 50 | 20–40 | 3–5 days |
| Deep laceration | 50 | 20–40 | 5–7 days |
| Major surgery — pre-operative | 80–100 | 60–80 | Post-operative 60–80 for 1–3 days, tapering |
When the response is poorer than the arithmetic predicted
| Observation | What it suggests | What to do |
|---|---|---|
| Measured level after the dose is far below the calculated target | An inhibitor — a neutralising alloantibody against factor VIII | Send a Bethesda inhibitor assay and a factor VIII recovery study, and contact the haemophilia centre before giving more factor VIII |
| A previously effective dose has stopped controlling bleeds | An inhibitor developing, commonly after intensive exposure such as surgery | Same: assay before escalating. More of a neutralised product does not work |
| Low-titre inhibitor confirmed | Factor VIII may still work at a higher dose | Haemophilia centre decision, with levels measured rather than predicted |
| High-titre inhibitor confirmed | Factor VIII will not raise the level whatever the dose | Bypassing agents — recombinant activated factor VII or activated prothrombin complex concentrate — and immune tolerance induction. This calculator no longer applies |
Half an international unit per kilogram for each 1 IU/dL
Factor VIII replacement is dosed on a single pharmacokinetic fact: one international unit of standard half-life factor VIII per kilogram of body weight raises the plasma level by about 2 IU/dL. Invert that and each 1 IU/dL of desired rise costs half an IU per kilogram, which is where the 0.5 in the formula comes from. A 70 kg adult who needs to reach 60 IU/dL from a baseline below 1 needs about 2,065 IU. Because IU/dL and percent of normal activity are the same number, the same equation appears in the literature written both ways.
The number that actually has to be chosen is the target, and it depends entirely on the bleed. The WFH third edition tabulates peak levels for each site: 40 to 60 IU/dL for a joint or superficial muscle bleed, 80 to 100 for iliopsoas, intracranial, throat and neck or gastrointestinal bleeding and for major surgery, 50 for a renal bleed or deep laceration. Those are given here as a selector rather than averaged, because averaging a joint bleed with an intracranial one produces a figure that is wrong for both. The table also publishes a lower-dose pattern for resource-constrained settings, and it is worth knowing which pattern a local protocol follows.
The half-life then decides everything about the rest of the treatment. Standard half-life factor VIII lasts about 12 hours in adults and less in young children, so a single infusion covers a fraction of a day. A joint bleed needs repeat dosing for one to two days; an intracranial bleed needs an initial peak followed by a maintenance phase running to two or three weeks. Reading the calculated figure as the whole of the treatment rather than as the first dose is the commonest way this arithmetic is misused.
The single most important thing to watch is the response. If a measured factor level after the dose is far below the calculated target, or a dose that used to control bleeds stops working, the likely explanation is an inhibitor — a neutralising alloantibody that develops in roughly a quarter to a third of people with severe haemophilia A. More of a neutralised product does not help, and management shifts to bypassing agents and immune tolerance induction, which this calculator does not cover. Send a Bethesda assay and speak to the haemophilia centre rather than escalating the dose. Every dose here supports a clinician's prescription rather than replacing it, and blood products are given against a clinical indication, not against a number.
Frequently asked questions
How do I calculate a factor VIII dose?
Multiply the weight in kilograms by the desired rise in IU/dL and then by 0.5. A 70 kg adult needing a rise of 59 IU/dL requires 70 × 59 × 0.5, which is 2,065 IU. The 0.5 exists because 1 IU/kg of standard half-life factor VIII raises the plasma level by about 2 IU/dL.
What factor VIII level should I aim for?
It depends on the bleed. WFH third edition gives 40 to 60 IU/dL for a joint or superficial muscle bleed, 80 to 100 for iliopsoas, intracranial, throat, neck or gastrointestinal bleeding and for major surgery, and 50 for a renal bleed or deep laceration.
How often does factor VIII need to be repeated?
Standard half-life factor VIII has a half-life of about 12 hours in adults and shorter in young children, so repeat dosing every 12 to 24 hours, or a continuous infusion for a major bleed. The calculated figure is a first dose, not a course of treatment.
Why is my patient not responding to factor VIII?
Suspect an inhibitor — a neutralising alloantibody against factor VIII, which develops in roughly a quarter to a third of people with severe haemophilia A. Send a Bethesda inhibitor assay and contact the haemophilia centre. Giving more of a neutralised product does not work; bypassing agents are needed.
Do I use the target level or the rise in the formula?
The rise, which is the target peak minus the baseline level. In severe haemophilia A the baseline is under 1 IU/dL so the two are nearly the same, but in mild disease with a baseline of 20 IU/dL, using the peak instead of the rise overdoses by about a third.
Related calculators
References
- Srivastava A, Santagostino E, Dougall A, et al. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia. 2020;26(Suppl 6):1–158.
- Collins PW, Chalmers E, Hart DP, et al. Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: a United Kingdom Haemophilia Centre Doctors' Organisation guideline. Br J Haematol. 2013;160(2):153–170.
- Rayment R, Chalmers E, Forsyth K, et al. Guidelines on the use of prophylactic factor replacement for children and adults with haemophilia A and B. Br J Haematol. 2020;190(5):684–695.
Medical Disclaimer: The tools and content provided here are for educational and reference purposes only. They are not intended to substitute for professional medical advice, diagnosis, or treatment. Clinical decisions should always be based on the comprehensive assessment of a qualified healthcare professional.